Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00096590 · ClinicalTrials.gov registry record
Detecting Abnormal Blood Clotting in Patients With Metastatic Cancer Undergoing Surgery
A clinical trial, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 60
- Enrollment target
NCT00096590: Completed study, sponsored by National Cancer Institute (NCI).
NCT00096590 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 60 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00096590 has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 60 participants
- Enrollment target
Study Summary
RATIONALE: A test that detects abnormal blood clotting in patients with cancer may help doctors plan cancer surgery. PURPOSE: This laboratory study is looking at a new blood test to detect abnormal clotting in patients with metastatic cancer undergoing surgery.
Interventions
- OTHER laboratory biomarker analysis
- OTHER physiologic testing
- PROCEDURE study of high risk factors
- OTHER immunoenzyme technique
- OTHER coagulation study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2004-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00096590
The ClinicalTrials.gov registry entry for NCT00096590 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT00096590 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00096590 about?
NCT00096590 is a clinical study titled "Detecting Abnormal Blood Clotting in Patients With Metastatic Cancer Undergoing Surgery". RATIONALE: A test that detects abnormal blood clotting in patients with cancer may help doctors plan cancer surgery. PURPOSE: This laboratory study is looking at a new blood test to detect abnormal clotting in patients with metastatic cancer undergoing surgery.
What is the current status of trial NCT00096590?
This trial is currently completed. The enrollment target is 60 participants. The study started on 2004-11.
What interventions are being tested in trial NCT00096590?
The interventions under investigation include: laboratory biomarker analysis (OTHER), physiologic testing (OTHER), study of high risk factors (PROCEDURE), immunoenzyme technique (OTHER), coagulation study (OTHER).
Who is sponsoring clinical trial NCT00096590?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.